Fresenius Medical Care appoints Joseph Turk as new Management Board Member for Care Enablement
Fresenius Medical Care (NYSE:FMS), the world's leading provider of renal disease products and services, has announced the appointment of Joseph E. Turk as new Management Board Member and CEO of Care Enablement, effective January 1, 2026.
Turk, currently Executive VP of Global Home and Critical Care Therapies and Head of US Commercial Operations, will succeed Dr. Katarzyna Mazur-Hofsäß, who plans to retire by year-end 2025. Having joined FMS in 2019 following the NxStage Medical acquisition, Turk brings extensive experience from roles at Boston Scientific, McKinsey & Company, and Deloitte.
The company serves approximately 300,000 dialysis patients through 3,676 clinics worldwide and maintains its position as the leading provider of dialysis products including machines and dialyzers.
Fresenius Medical Care (NYSE:FMS), il principale fornitore mondiale di prodotti e servizi per la malattia renale, ha annunciato la nomina di Joseph E. Turk come nuovo Membro del Management Board e CEO di Care Enablement, con effetto dal 1 gennaio 2026.
Turk, attualmente VP esecutivo delle Global Home and Critical Care Therapies e Capo delle Operazioni Commerciali negli Stati Uniti, succederà a Dr. Katarzyna Mazur-Hofsäß, che prevede di ritirarsi entro la fine del 2025. Avendo dato l’ingresso in FMS nel 2019 dopo l’acquisizione di NxStage Medical, Turk porta una vasta esperienza maturata in ruoli presso Boston Scientific, McKinsey & Company e Deloitte.
L’azienda serve circa 300.000 pazienti in dialisi attraverso 3.676 cliniche in tutto il mondo e mantiene la sua posizione di leader tra i fornitori di prodotti per la dialisi, inclusi macchinari e dializzatori.
Fresenius Medical Care (NYSE:FMS), el principal proveedor mundial de productos y servicios para la enfermedad renal, ha anunciado la designación de Joseph E. Turk como nuevo Miembro de la Junta de Gestión y CEO de Care Enablement, con efecto a partir del 1 de enero de 2026.
Turk, actualmente Vicepresidente Ejecutivo de Terapias Globales Domiciliarias y Críticas y Director de Operaciones Comerciales en Estados Unidos, sucederá al Dr. Katarzyna Mazur-Hofsäß, que planea jubilarse a finales de 2025. Habiéndose incorporado a FMS en 2019 tras la adquisición de NxStage Medical, Turk aporta una amplia experiencia en roles en Boston Scientific, McKinsey & Company y Deloitte.
La empresa atiende aproximadamente a 300.000 pacientes de diálisis a través de 3.676 clínicas en todo el mundo y mantiene su posición como proveedor líder de productos de diálisis, incluidas máquinas y diálisis.
Fresenius Medical Care (NYSE:FMS)는 세계 최대의 신장 질환 제품 및 서비스 공급업체로, Joseph E. Turk 를 Care Enablement의 신규 경영 이사회 구성원 겸 CEO로 2026년 1월 1일부로 임명했다고 발표했습니다.
Turk는 현재 글로벌 가정용 및 중환자 치료 요법 부문 부사장 겸 미국 상업 운영 책임자로, 2025년 말 은퇴할 계획인 Dr. Katarzyna Mazur-Hofsäß를 승계합니다. NxStage Medical 인수 후 2019년에 FMS에 합류한 Turk는 Boston Scientific, McKinsey & Company, Deloitte에서의 다년간 경험을 보유하고 있습니다.
이 회사는 전 세계 3,676개의 클리닉을 통해 약 30만 명의 투석 환자를 서비스하고 있으며, 기계 및 투석기를 포함한 투석 제품의 선두 공급자로서의 지위를 유지하고 있습니다.
Fresenius Medical Care (NYSE:FMS), leader mondial des produits et services pour les maladies rénales, a annoncé la nomination de Joseph E. Turk en tant que nouveau membre du Management Board et PDG de Care Enablement, à compter du 1er janvier 2026.
Turk, actuellement vice-président exécutif des thérapies Global Home and Critical Care et chef des opérations commerciales aux États-Unis, succédera au Dr. Katarzyna Mazur-Hofsäß, qui prévoit de partir à la retraite d’ici la fin de 2025. Ayant rejoint FMS en 2019 après l’acquisition de NxStage Medical, Turk apporte une vaste expérience issues de postes chez Boston Scientific, McKinsey & Company et Deloitte.
L’entreprise dessert environ 300 000 patients dialysés via 3 676 cliniques dans le monde et demeure le principal fournisseur de produits de dialyse, y compris les machines et les dialyseurs.
Fresenius Medical Care (NYSE:FMS), der weltweit führende Anbieter von Produkten und Dienstleistungen im Bereich Nierenerkrankungen, hat die Ernennung von Joseph E. Turk zum neuen Mitglied des Management Boards und CEO von Care Enablement mit Wirkung zum 1. Januar 2026 bekannt gegeben.
Turk, derzeit Executive Vice President der Global Home and Critical Care Therapies und Leiter der US-Vertriebsaktivitäten, wird Nachfolger von Dr. Katarzyna Mazur-Hofsäß, die plant, Ende 2025 in den Ruhestand zu gehen. Nachdem er 2019 nach der Übernahme von NxStage Medical zu FMS kam, bringt Turk umfangreiche Erfahrungen aus Positionen bei Boston Scientific, McKinsey & Company und Deloitte mit.
Das Unternehmen betreut ungefähr 300.000 Dialysepatienten weltweit in 3.676 Kliniken und behält seine Position als führender Anbieter von Dialyseprodukten, einschließlich Maschinen und Dialysatoren.
Fresenius Medical Care (NYSE:FMS)، المزود العالمي الرائد لمنتجات وخدمات أمراض الكلى، أعلن تعيين Joseph E. Turk كعضو مجلس الإدارة التنفيذي الجِدِيد وCEO لـ Care Enablement، اعتباراً من 1 يناير 2026.
Turk، الذي يشغل حالياً منصب نائب الرئيس التنفيذي للعلاجيات العالمية المنزلية والرعاية الحادّة وكبير مسؤولي العمليات التجارية في الولايات المتحدة، سيخلف Dr. Katarzyna Mazur-Hofsäß، التي تخطط للتقاعد بحلول نهاية عام 2025. بعد انضمامه إلى FMS في 2019 عقب استحواذ NxStage Medical، يجلب Turk خبرة واسعة من مناصب في Boston Scientific وMcKinsey & Company وDeloitte.
تخدم الشركة نحو 300,000 مريض بغسيل الكلى عبر 3,676 عيادة حول العالم وتحافظ على مكانتها كمزود رائد لمنتجات الغسيل الكلوي بما في ذلك الآلات والغُرَف.
Fresenius Medical Care (NYSE:FMS)，全球领先的肾病产品与服务提供商，宣布任命 Joseph E. Turk 为 Care Enablement 的新管理董事会成员兼首席执行官，任命于 2026 年 1 月 1 日生效。
Turk 目前为全球家庭与重症护理治疗的执行副总裁及美国商务运营主管，将接任计划于2025 年底退休的 Dr. Katarzyna Mazur-Hofsäß。自 2019 年并入 FMS（来自 NxStage Medical 收购）以来，Turk 在 Boston Scientific、McKinsey & Company 以及 Deloitte 的职位上积累了丰富经验。
公司通过全球 3,676 家诊所为约 30 万名透析患者 提供服务，保持着作为透析产品（包括透析机与透析器）的领先供应商的地位。
- Internal succession ensures continuity in leadership and strategy execution
- Appointment supports ongoing margin improvement initiatives in Care Enablement segment
- New leadership to drive US rollout of innovative 5008X CAREsystem
- None.
- Effective January 1, 2026, Joseph Turk will join the Management Board as Chief Executive Officer of the global operating segment Care Enablement
- As part of a planned transition Dr. Katarzyna Mazur-Hofsäß will retire by year end
BAD HOMBURG,
Mr. Turk will succeed Dr. Katarzyna Mazur-Hofsäß (62) as part of a planned transition after she informed the Supervisory Board of her intention to retire. Dr. Mazur-Hofsäß joined Fresenius Medical Care in 2018 and has been leading Care Enablement since its creation in 2022.
Mr. Turk joined Fresenius Medical Care in 2019, following the acquisition of NxStage Medical. He currently serves as Executive Vice President of Global Home and Critical Care Therapies as well as Head of US Commercial Operations. Before joining, he held positions at Boston Scientific, McKinsey & Company and Deloitte and holds a master's in marketing, finance and operations from the J.L. Kellogg Graduate School of Management, Northwestern University (
"We are delighted to have Joe Turk join the Management Board of Fresenius Medical Care. With his expertise and commitment, he will be instrumental in continuing the margin improvement track of Care Enablement, successfully rolling out the innovative 5008X CAREsystem to the
Helen Giza, CEO and Chair of the Management Board, said: "Joe joins the Fresenius Medical Care Management Board as a well-known colleague with a strong proven track record. He will be a valuable member of my leadership team and ensure uninterrupted execution of our FME Reignite strategy in this important phase for Care Enablement. I would like to thank Katarzyna for her significant contribution to fundamentally transforming and reshaping Care Enablement. I wish her well in her retirement."
Joe Turk said: "I am excited to join the Fresenius Medical Care Management Board at a time when it has embarked on the FME Reignite strategy, where Care Enablement will play a crucial role in innovating for patients, caregivers and customers. I look forward to continuing working with all committed employees worldwide."
About Fresenius Medical Care:
Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.2 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,676 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 300,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the Company's website at www.freseniusmedicalcare.com.
Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care's reports filed with the
Media contact
Christine Peters
T +49 160 60 66 770
christine.peters@freseniusmedicalcare.com
Contact for analysts and investors
Dr. Dominik Heger
T +49 6172 609 2601
dominik.heger@freseniusmedicalcare.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/fresenius-medical-care-appoints-joseph-turk-as-new-management-board-member-for-care-enablement-302572521.html
SOURCE Fresenius Medical Care Holdings, Inc.
FAQ
Who is the new Management Board Member for Care Enablement at Fresenius Medical Care (FMS)?
What is Joseph Turk's current role at Fresenius Medical Care?
Why is Dr. Katarzyna Mazur-Hofsäß leaving Fresenius Medical Care (FMS)?
What are Fresenius Medical Care's (FMS) current operational statistics?
What strategic initiatives will Joseph Turk oversee at Fresenius Medical Care?
